ADXN

Addex Therapeutics Ltd [ADXN] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

ADXN Stock Summary

In the News

ADXN Financial details

Company Rating
-
Market Cap
37.61M
Income
-11.35M
Revenue
2.05M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
24
Optionable
No
Shortable
Yes
Earnings
06 May 2024
P/E
-0.38
Forward P/E
-
PEG
0.06
P/S
4.29
P/B
1.12
P/C
-
P/FCF
-0.84
Quick Ratio
2.66
Current Ratio
2.97
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.17
EPS next Y
-
EPS next Q
-
EPS this Y
2.22%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
45.48%
Revenue last 5Y
-25.12%
Revenue Q/Q
-48.05%
EPS Q/Q
-8.63%
-
-
-
-
SMA20
-
SMA50
12.5%
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-188%
ROE
-242%
ROC
-2.64%
Gross Margin
100%
Oper. Margin
-541%
Profit Margin
-563%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
5.0-27.9
52W High
-65.56%
52W Low
+86%
RSI
52
Rel Volume
0.56
Avg Volume
16.34K
Volume
9.22K
Perf Week
-3.12%
Perf Month
2.99%
Perf Quarter
14.53%
Perf Half Y
20.94%
-
-
-
-
Beta
1.759
-
-
Volatility
0.23%, 0.48%
Prev Close
0.54%
Price
9.3
Change
-5.01%

Something similar

Top by Market Cap
MSFT
CMC.DE
BRK-A
V
TL0.DE
Same Sector
NXEN
NMTC
RGDXQ
GRANULES.NS
PRAX
Same Price Range
EDG2.L
CPTP
0038.HK
IGLT.MI
300015.SZ
Similar Market Cap
DEL2.DE
CCRV
LPCN
TCBT.DE
HGGAX

Company Profile

Healthcare Biotechnology
  • Volume Average 16.34K
  • Market Capitalization 37.61M
  • Employee 24
  • CEO Mr. Timothy Mark Dyer
  • Headquarters Geneva,CH
  • IPO Date 2020-02-12
  • Website https://www.addextherapeutics.com

Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of oral small molecule allosteric modulators of G-protein coupled receptors. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia, and dystonia; ADX71149 for epilepsy and undisclosed CNS disorders; and GABAB PAM for addiction. It has license and collaboration agreement with Janssen Pharmaceuticals Inc.; Indivior PLC; and The Charcot–Marie–Tooth Association. The company was formerly known as Addex Pharmaceuticals Ltd and changed its name to Addex Therapeutics Ltd in March 2012. Addex Therapeutics Ltd was founded in 2002 and is headquartered in Geneva, Switzerland.